A clinical trial to see the role of procalcitonin (a blood test which detects bacterial infection) in the usage of antibiotics in acute pancreatitis patients
- Conditions
- Health Condition 1: K859- Acute pancreatitis, unspecified
- Registration Number
- CTRI/2022/08/044601
- Lead Sponsor
- JIPMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients over the age of 18 years of age
2. A diagnosis of acute pancreatitis requiring two of the following three features [7]:
I. abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epigastric pain often radiating to the back)
II. serum lipase activity (or amylase activity) at least three times greater than the upper limit of normal
III. Characteristic findings of acute pancreatitis on contrast-enhanced computed tomography (CECT), magnetic resonance imaging (MR) or transabdominal ultrasonography
1. Comorbidities requiring prolonged antibiotic therapyââ?¬â?such as infective endocarditis
2. Severely immunocompromised patientsââ?¬â?such as those with human immunodeficiency virus and with a CD4 count of less than 200 cells/mm3 ; neutropenic patients ( < 500 neutrophils/mm3 )
3. Patients on immunosuppressive therapy
4. Previous thyroid surgery
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare antibiotic usage in terms of Daily Defined Dose (DDD) between patients treated conventionally and those in which treatment is guided by procalcitonin levels.Timepoint: 90 days
- Secondary Outcome Measures
Name Time Method 1)Mortality of the patient, <br/ ><br>2)Length of hospital stay, <br/ ><br>3)Clinical infections such as pneumonia, enteritis or intra-abdominal infection <br/ ><br>4)Isolates of multi-resistant bacteria from the intra-abdominal collection aspirates, <br/ ><br>5)Incidence of multi-resistant organism bacteraemia, <br/ ><br>6)Incidence of infected pancreatic necrosis (IPN)ââ?¬â?defined either as a result of fine needle aspiration (FNA), radiological evidence of gas in a peri-pancreatic collection or positive microbiological cultures from surgical or post-mortem specimens, <br/ ><br>7)Need for radiological, endoscopic or surgical intervention, <br/ ><br>8)Survival at 90 days (through telephonic follow up), <br/ ><br>9)Re-admission to hospital within 4 weeks of onset of index episode (through telephonic follow up). <br/ ><br>Timepoint: All the secondary outcomes are taken into consideration within 90 days of hospital admission